Abera Bioscience ABNGM: ABERA

ABERA: Positive Q1 2025 result and strong vaccine pipeline progress, supported by grants

· Issued by Abera Bioscience AB

Abera Bioscience reported a positive Q1 2025 net result, driven by grant income and progress in vaccine R&D, with strong preclinical data and regulatory support for clinical trials. Continued funding from CEPI and UK Vaccine Network secures operations.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Abera Bioscience AB on 6ix

Earlier from Abera Bioscience

Later from Abera Bioscience

All Abera Bioscience news releases